Topical pimecrolimus does not prolong clear graft survival in a rat keratoplasty model.
BACKGROUND
Long-term application of topical steroids following penetrating keratoplasty is disadvantageous due to side effects (steroid response, cataract, surface disorders). In this study we investigated the efficacy of topical pimecrolimus regarding clear graft survival following allogeneic orthotopic keratoplasty in rats.


METHODS
A total of 46 penetrating keratoplasties were performed using Fisher rats (allogeneic groups) and Lewis rats (syngeneic group) as donors and Lewis rats as recipients: group 1 (n = 11), allogeneic control without therapy; group 2 (n = 12), syngeneic control; group 3 (n = 11), mycophenolate mofetil (MMF) 40 mg/kg body weight; group 4 (n = 12), pimecrolimus 1% ointment twice daily. Four animals of each group were sacrificed for immunohistological evaluation on day 14. Therapy was administered for 18 days. The grafts were evaluated once every 3 days regarding opacity, oedema and vascularisation. Graft rejection was defined as total graft opacity.


RESULTS
Mean rejection-free graft survival was 11.4 days in group 1 (allogeneic control), 100 days (total follow-up time) in group 2 (syngeneic control), 24.0 days in group 3 (MMF 40 mg/kg) and 11.6 days in group 4 (topical pimecrolimus). The immunohistological evaluation showed no statistically significant difference in cell infiltration of the grafts comparing groups 1 and 4.


CONCLUSIONS
Topical immunosuppression with pimecrolimus does not prolong graft survival in the allogeneic keratoplasty rat model.
Birnbaum
Florian
F
University Eye Hospital, Killianstr. 5, 79106 Freiburg, Germany. florian.birnbaum@uniklinik-freiburg.de
Schwartzkopff
Johannes
J
Scholz
Christoph
C
Reinhard
Thomas
T
D000287:Administration, Topical; D000818:Animals; D015703:Antigens, CD / Q000378:metabolism; D003315:Cornea / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D004195:Disease Models, Animal; D005260:Female; D006085:Graft Survival / Q000187:drug effects*; D007124:Immunoenzyme Techniques; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015948:Keratoplasty, Penetrating; D051381:Rats; D011916:Rats, Inbred F344; D011917:Rats, Inbred Lew; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*
D015703:Antigens, CD; D007166:Immunosuppressive Agents; C117268:pimecrolimus; D016559:Tacrolimus
Ophthalmologe. 2007 May;104(5):373-80
17387480
Vet Ophthalmol. 2005 Jan-Feb;8(1):39-46
15644099
Jpn J Ophthalmol. 1989;33(2):212-20
2474684
Br J Ophthalmol. 1998 Jun;82(6):700-3
9797676
Br J Ophthalmol. 2004 Jul;88(7):915-9
15205237
Klin Monbl Augenheilkd. 2002 Mar;219(3):125-31
11987039
Transpl Int. 2005 Feb;18(2):193-7
15691272
Int J Clin Pract. 2005 Aug;59(8):969-74
16033622
Ophthalmologe. 2007 May;104(5):381-7
17387481
Transplantation. 2000 Nov 15;70(9):1397-401
11087159
Invest Ophthalmol Vis Sci. 1997 Apr;38(5):901-9
9112986
J Dermatolog Treat. 2005 Aug;16(3):142-8
16096179
Ophthalmologe. 2007 May;104(5):371-2
17380336
Transplantation. 2005 Apr 27;79(8):964-8
15849551